Inhibiting HIPK2 expression delays EMT progression and improves renal fibrosis in diabetic kidney disease

Diabetic kidney disease (DKD) is a severe microvascular complication of diabetes, often leading to end-stage renal disease. A key pathological driver is epithelial-to-mesenchymal transition (EMT) in renal tubular epithelial cells, mediated by TGF-β1. This process involves cells losing epithelial characteristics and gaining mesenchymal ones, contributing to renal interstitial fibrosis (RIF). Current treatments often fail to halt progression, highlighting the need for novel therapeutic targets. This study investigates the role of homoeotic domain-interacting protein kinase 2 (HIPK2) in this pathway.

Researchers validated renal interstitial fibrosis (RIF) and EMT as pathological foundations in both clinical DKD patients and DKD mouse models. They established a DKD-EMT cellular model using human renal tubular epithelial cells (HK-2) stimulated with TGF-β1 combined with high glucose. The primary intervention involved inhibiting HIPK2 expression. They assessed EMT progression and RIF improvement as key endpoints. Specific dosing, route, frequency, or duration for HIPK2 inhibition were not detailed in the abstract.

The study confirmed that renal interstitial fibrosis (RIF) and EMT are significant pathological foundations for DKD progression, validated across clinical DKD patients and DKD mouse models. They observed elevated expression of HIPK2 in DKD conditions. The core finding demonstrated a crucial role for HIPK2 in EMT regulation.

Inhibiting HIPK2 expression significantly delayed EMT progression and improved RIF in the DKD-EMT cellular model. This suggests a direct regulatory role for HIPK2 in EMT within the context of DKD. The study identified HIPK2 as a potential therapeutic target for DKD-EMT, providing a novel strategy for DKD progression. Specific quantitative data, such as percentages or p-values, were not provided in the abstract.